ZCZhanna V. Chubukina

Zhanna V. Chubukina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhanna V. Chubukina has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Interlaboratory consensus on the immunophenotypic diagnosis of chronic lymphocytic leukemia: Recommendations for the preparation of cytometric study reports and the selection of panels of monoclonal antibodies

    by E. N. Parovichnikova, E. V. Naumova, V. N. Dvirnyk, E. I. Zakharko, D. G. Drokova, К. A. Nikiforova, E. V. Babenko, Е. А. Belyakova, Yu. V. Mirolyubova, N. V. Pronkina, et al.

    Introduction. Immunophenotyping is a key diagnostic method for chronic lymphocytic leukemia (CLL), the most common lymphoproliferative disorder (LPD) in middle-aged and elderly individuals. Given the high prevalence of CLL, there is a need to standardize approaches to its immunophenotypic diagnosis, including the development of standardized panels of monoclonal antibodies, recommendations for sample preparation, and the formulation of reports to improve diagnostic accuracy.Aim: to develop a unified laboratory report form and a standardized approach to using the necessary and sufficient combination of labeled monoclonal antibodies for the diagnosis of CLL.Main findings. An All-Russian working group was formed under the National Hematological Society (NHS) to discuss key issues in the laboratory diagnosis of CLL. The primary focus was on problems related to immunophenotyping. Consensus decisions were made regarding the creation of a unified laboratory report form and a standardized approach to using the necessary and sufficient combination of labeled monoclonal antibodies for the diagnosis of CLL. The monoclonal antibody panel should include antibodies detecting CD19, CD20, CD5, CD23, and surface immunoglobulin light chains (k and λ). To differentiate CLL from other B-LPDs, additional markers such as CD43, CD200, CD10, CD22, and CD38 are recommended. The report form should include, along with patient information and sample type, the following: a list of used monoclonal antibodies, the flow cytometer model, the count of leukocytes and lymphocytes, the immunophenotype of the identified tumor population with emphasis on aberrant markers, the absolute count of pathological clone cells, and the final immunophenotypic variant of CLL or B-LPD.

  • The specific features of diagnosis of mixed-phenotype acute leukemia: A combination of B-cell antigen expressions according to the results of flow cytometry and morphological markers of myeloid differentiation in blast cells: A clinical case

    by S. V. Gritsaev, I. I. Kostroma, G. M. Ryadnova, S. A. Tiranova, Zh. V. Chubukina, V. A. Balashova, M. N. Zenina, I. S. Martynkevich, N. A. Potikhonova, K. M. Abdulkadyrov

    Издательство Медиа Сфера - 25 медицинских журналов общим тиражом около 500 000 экземпляров в год, представлены в международных базах данных Scopus, Medline, и Google Scolar, включены в перечень изданий ВАК, представлены в РИНЦ


  • An inter-laboratory comparison of PNH clone detection by high-sensitivity flow cytometry in a Russian cohort

    by Alexandra A. Sipol, Vyacheslav I. Borisov, Elena V. Naumova, Elena V. Boyakova, Dimitry I. Yakunin, Tatyana V. Glazanova, Zhanna V. Chubukina, Natalya V. Pronkina, Alexander M. Popov, Leonid I. Saveliev, et al.

    Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal stem cell disorder characterized by partial or absolute deficiency of glycophosphatidyl-inositol (GPI) anchor-linked surface proteins on blood cells. A lack of precise diagnostic standards for flow cytometry has hampered useful comparisons of data between laboratories. We report data from the first study evaluating the reproducibility of high-sensitivity flow cytometry for PNH in Russia. PNH clone sizes were determined at diagnosis in PNH patients at a central laboratory and compared with follow-up measurements in six laboratories across the country. Analyses in each laboratory were performed according to recommendations from the International Clinical Cytometry Society (ICCS) and the more recent 'practical guidelines'. Follow-up measurements were compared with each other and with the values determined at diagnosis. PNH clone size measurements were determined in seven diagnosed PNH patients (five females, two males: mean age 37 years); five had a history of aplastic anemia and three (one with and two without aplastic anemia) had severe hemolytic PNH and elevated plasma lactate dehydrogenase. PNH clone sizes at diagnosis were low in patients with less severe clinical symptoms (0.41-9.7% of granulocytes) and high in patients with severe symptoms (58-99%). There were only minimal differences in the follow-up clone size measurement for each patient between the six laboratories, particularly in those with high values at diagnosis. The ICCS-recommended high-sensitivity flow cytometry protocol was effective for detecting major and minor PNH clones in Russian PNH patients, and showed high reproducibility between laboratories.